Drugs / Kylo-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06783881 | Mar → Dec 2025 overdue | hypertriglyceridemia | Kylonova (Xiamen) Biopharma co., LTD. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kylo-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783881 ↗ |
| Route | Subcutaneous | “Single ascending doses of Kylo-12 administered subcutaneously (SC).” NCT06783881 ↗ |